Substantially reduced incidence of genital warts in women and men six years after HPV vaccine availability in Sweden.

BACKGROUND Between 2007 and 2011, opportunistic HPV-vaccination was available in Sweden and partially subsidized to girls aged 13-17, reaching a ∼30% overall coverage. METHODS All Swedish women/men aged 15-44 were followed between 2006 and 2012 for condyloma. Average annual percent changes (AAPCs) in incidence were estimated. RESULTS Substantial decreases were seen in women aged 15-24 from 2008-onwards (AACP-range: -8.5% to -18.5%); similar effects were seen for men aged 15-29 (AACP-range: -7.0% to -16.6%) from 2010-onwards. DISCUSSION Despite low population vaccination coverage in women and no coverage in men, similar condyloma incidence reductions were observed among men and women, with delays of >1 years in men.

• Publication year

  2018

• Venue

  Vaccine

• Publication date

  2018-04-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2018.02.097PMID 29523448
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark.

  2013cited by this paper
• Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data

  2013cited by this paper
• Quadrivalent Human Papillomavirus Vaccine Effectiveness: A Swedish National Cohort Study

  2013cited by this paper
• Significant Decrease in the Incidence of Genital Warts in Young Danish Women After Implementation of a National Human Papillomavirus Vaccination Program

  2013cited by this paper
• Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability.

  2012cited by this paper
• Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap.

  2010cited by this paper
• Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.

  2009cited by this paper
• Hematologic and biochemical changes associated with human T lymphotropic virus type 1 infection in Jamaica: a report from the population-based blood donors study.

  2007cited by this paper
• Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection.

  2007cited by this paper
• Estimating regression models with unknown break‐points

  2003cited by this paper

• Population-Based Age-Period-Cohort Analysis of Declining Human Papillomavirus Prevalence

  2025cites this paper
• Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV‐related disease and harms from vaccination

  2025cites this paper
• Should routine HPV vaccination programs include males 25–29 years? A systematic review and global meta-analysis

  2025cites this paper
• Population-Level Impact of Human Papillomavirus Vaccination on the Incidence of Genital Warts in Sweden

  2025influential citation
• Children’s and parents’ attitudes to and knowledge about HPV vaccination following a targeted information intervention

  2024cites this paper
• Surgical Management of Giant Condyloma Acuminata Involving Vulva, Perineum and Perianal Area

  2024cites this paper
• The Burden of Genital Warts in Finland: Cross-Sectional Analysis of the Prevalence and Direct Medical Costs in 2018

  2023cites this paper
• Attitudes Toward HPV Vaccination in Sweden: A Survey Study

  2022cites this paper
• Ten-Year Trend in Emergency Department Visits for Sexually Transmitted Infections among Adolescents: A Retrospective Cross-Sectional Study in Italy

  2022cites this paper
• Real-world impact and effectiveness of the quadrivalent HPV vaccine: an updated systematic literature review

  2022influential citation
• Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial

  2022cites this paper
• Incidence of anogenital warts after the introduction of the quadrivalent HPV vaccine program in Manitoba, Canada

  2022cites this paper
• Real-world impact and effectiveness assessment of the quadrivalent HPV vaccine: a systematic review of study designs and data sources

  2021cites this paper
• Morphological and structural evaluation of nanoparticles loaded with tea tree oil for the therapeutic treatment of HPV

  2021cites this paper
• Sexually Transmitted Infections Treatment Guidelines, 2021

  2021cites this paper
• HPV Vaccines: Myths and Facts

  2020cites this paper
• Impact of HPV vaccination on cervical screening performance: a population-based cohort study

  2020cites this paper
• Low-risk Human Papillomavirus: Genital Warts, Cancer and Respiratory Papillomatosis

  2020cites this paper
• HPV Vaccination and the Risk of Invasive Cervical Cancer.

  2020cites this paper
• Prevention and prognosis of cervical cancer : the interplay of human papillomavirus, vaccination and screening

  2020cites this paper
• Municipally sponsored human papillomavirus (HPV) vaccination of boys in Slovenia: the first 4 years.

  2019cites this paper
• Cost-effectiveness analysis of HPV vaccination of boys in Belgium

  2019influential citation
• Changes in Cervical Human Papillomavirus (HPV) Prevalence at a Youth Clinic in Stockholm, Sweden, a Decade After the Introduction of the HPV Vaccine

  2019cites this paper
• Human papillomavirus vaccination: review of the current evidence

  2019cites this paper
• POPULATION-LEVEL IMPACT AND HERD EFFECTS FOLLOWING THE INTRODUCTION OF HUMAN

  2019cites this paper
• Immunogenicity and safety of human papillomavirus vaccine coadministered with other vaccines in individuals aged 9-25 years: A systematic review and meta-analysis.

  2019cites this paper
• Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.

  2019cites this paper
• Recent advances in prophylactic human papillomavirus (HPV) vaccination: a review of key literature published between September 2017 and September 2018.

  2018cites this paper
• Access to HPV vaccination for boys in the United Kingdom

  2018cites this paper
• The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?

  2018cites this paper